Antares and Ferring Sign Licensing Agreement for NOCDURNA

shot by IP News Shots / 2:06 pm on 05 October, 2020

An exclusive licensing agreement has been signed between Antares Pharma, Inc., and Ferring Pharmaceuticals for the latter’s drug NOCDURNA used in the treatment of nocturia due to nocturnal polyuria in adults. As per the financial terms of the agreement, Ferring will receive an upfront payment of $5 million and an additional $2.5 million on the completion of one year of executing the agreement. Ferring is also eligible for tiered royalties and milestone payments potentially adding up to $17.5 million.

Read More at: https://www.streetinsider.com/dr/news.php?id=17421428&gfv=1

Industry: Pharmaceuticals | Type of IP: Deals - Licensing